Maraviroc reactivates HIV with a potency similar to that of other latency reversing drugs without inducing toxicity in CD8 T cells

Maraviroc reactivates HIV with a potency similar to that of other latency reversing drugs without inducing toxicity in CD8 T cells

Bibliographic Details
Main Authors:	S. Moreno, M. López Huertas, L. Jiménez Tormo, N. Madrid Elena, C. Gutierrez, M.J. Vivancos, L. Luna
Format:	Article
Language:	English
Published:	Elsevier 2019-12-01
Series:	Journal of Virus Eradication
Online Access:	http://www.sciencedirect.com/science/article/pii/S2055664020302120

Similar Items

The CCR5-antagonist Maraviroc reverses HIV-1 latency in vitro alone or in combination with the PKC-agonist Bryostatin-1
by: María Rosa López-Huertas, et al.
Published: (2017-05-01)

Prolonged administration of maraviroc reactivates latent HIV in vivo but it does not prevent antiretroviral-free viral rebound
by: María Rosa López-Huertas, et al.
Published: (2020-12-01)

Maraviroc (Celsentri) in HIV treatment
by: Viola Sacchi
Published: (2008-01-01)

30LB Maraviroc administration is associated to reversion of latent HIV-1 through NFkB in ART suppressed patients
by: N. Madrid-Elena, et al.
Published: (2016-07-01)

Effectiveness and cost of treatment with maraviroc in HIV infection
by: Viola Sacchi, et al.
Published: (2009-01-01)

The CCR5 antagonist maraviroc exerts limited neuroprotection without improving neurofunctional outcome in experimental pneumococcal meningitis
by: Ngoc Dung Le, et al.
Published: (2022-07-01)

Without Latency
by: Hulbert, Adam
Published: (2015-09-01)

Lack of effect of Maraviroc intensification on blood and gut reservoir.
by: Tiraboschi, J, et al.
Published: (2016)

Short-term maraviroc exposure, a clinical approach to decide on maraviroc prescription in HIV-1-infected treatment-naïve patients
by: Gonzalez-Serna A, et al.
Published: (2016-01-01)

Markers of HIV reservoir size and immune activation after treatment in acute HIV infection with and without raltegravir and maraviroc intensification
by: Jintanat Ananworanich, et al.
Published: (2015-04-01)

23 Understanding the effects of latency reversing agents on HIV RNA splicing: implications for latency reversal
by: T.M. Mota, et al.
Published: (2016-07-01)

Maraviroc: a review of its use in HIV infection and beyond
by: Woollard SM, et al.
Published: (2015-10-01)

Are BET Inhibitors yet Promising Latency-Reversing Agents for HIV-1 Reactivation in AIDS Therapy?
by: Thanarat Salahong, et al.
Published: (2021-05-01)

Reactivation capacity by latency reversing agents ex vivo correlates with the size of the HIV-1 reservoir
by: Gilles Darcis, et al.
Published: (2016-05-01)

Synergistic anti-HIV-1 activity of griffithsin with tenofovir, maraviroc and enfuvirtide
by: Schols Dominique, et al.
Published: (2011-10-01)

Impact of maraviroc on immune restoration in an advanced stage HIV-infected patient
by: Poizot-Martin Isabelle, et al.
Published: (2010-05-01)

Maraviroc – a CCR5 antagonist for the treatment of HIV-1 infection
by: Elna eVan Der Ryst
Published: (2015-06-01)

Development and evaluation of mucoadhesive bigel containing tenofovir and maraviroc for HIV prophylaxis
by: Margaret O. Ilomuanya, et al.
Published: (2020-11-01)

New Concepts in Therapeutic Manipulation of HIV-1 Transcription and Latency: Latency Reversal versus Latency Prevention
by: Catherine A. Lewis, et al.
Published: (2023-07-01)

Regulation of Latency and Reactivation by Human Cytomegalovirus miRNAs
by: Nicole L. Diggins, et al.
Published: (2021-02-01)

Approaches to discover latency-reversing agents
Published: (2015-12-01)

Combinatorial latency reversal activity of inhibitor of apoptosis antagonists with mechanistically distinct classes of HIV latency reversal agents
by: Shane D. Falcinelli, et al.
Published: (2019-12-01)

Regulation of KSHV Latency and Lytic Reactivation
by: Grant Broussard, et al.
Published: (2020-09-01)

Latency reactivating agents: impact on human macrophages physiology and susceptibility to HIV-1 infection
by: L. Hany, et al.
Published: (2019-07-01)

Regulation of the MIE Locus During HCMV Latency and Reactivation
by: Abigail L. Dooley, et al.
Published: (2020-10-01)

Editorial: The relevance of molecular mechanisms in HIV-1 latency and reactivation from latency
by: Alexander O. Pasternak, et al.
Published: (2023-04-01)

Role of maraviroc and/or rapamycin in the liver of IL10 KO mice with frailty syndrome.
by: Laura Pérez-Martínez, et al.
Published: (2024-01-01)

HIV-1 Coreceptor Usage Assessment by Ultra-Deep Pyrosequencing and Response to Maraviroc.
by: Christophe Rodriguez, et al.
Published: (2015-01-01)

Use of maraviroc, the first CCR5 receptor antagonist, in HIV treatment regimens
by: A V Kravchenko
Published: (2013-11-01)

Advances in Model Systems for Human Cytomegalovirus Latency and Reactivation
by: Lindsey B. Crawford, et al.
Published: (2022-02-01)

Corrigendum: Editorial: The relevance of molecular mechanisms in HIV-1 latency and reactivation from latency
by: Alexander O. Pasternak, et al.
Published: (2023-05-01)

Coenzyme Q10 and Its Therapeutic Potencies Against COVID-19 and Other Similar Infections: A Molecular Review
by: Mohammad Fakhrolmobasheri, et al.
Published: (2023-03-01)

Combinations of Histone Deacetylase Inhibitors with Distinct Latency Reversing Agents Variably Affect HIV Reactivation and Susceptibility to NK Cell-Mediated Killing of T Cells That Exit Viral Latency
by: Daniela A. Covino, et al.
Published: (2021-06-01)

The efficacy and tolerability of latency-reversing agents in reactivating the HIV-1 reservoir in clinical studies: a systematic review
by: Quinten Debrabander, et al.
Published: (2023-09-01)

Impact of IL-15 and latency reversing agent combinations in the reactivation and NK cell-mediated suppression of the HIV reservoir
by: Daniela Angela Covino, et al.
Published: (2022-11-01)

Patient-derived HIV reservoirs can be stably engrafted into NSG mice and reactivated by latency-reversing agents in vivo
by: A. Ward, et al.
Published: (2017-12-01)

O6 Reactivation capacity by latency reversing agents ex vivo correlates with the size of the HIV-1 reservoir
by: Gilles Darcis, et al.
Published: (2016-09-01)

Selective miRNA Modulation Fails to Activate HIV Replication in In Vitro Latency Models
by: María Rosa López-Huertas, et al.
Published: (2019-09-01)

Experimental Systems for Measuring HIV Latency and Reactivation
by: Koh Fujinaga, et al.
Published: (2020-11-01)

BK polyomavirus: latency, reactivation, diseases and tumorigenesis
by: Xianfeng Zhou, et al.
Published: (2023-09-01)